Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes

BACKGROUND: The reduced drug accumulation based on enhanced drug efflux and metabolic capacity, identified in triclabendazole (TCBZ)-resistant Fasciola hepatica may contribute to the development of resistance to TCBZ. The aim of this work was to evaluate the pharmacokinetics and clinical efficacy of...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Ceballos, Laura, Moreno, Laura, Alvarez, Luis, Shaw, Laura, Fairweather, Ian, Lanusse, Carlos
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2010
Teme:
Research article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2829539/
https://ncbi.nlm.nih.gov/pubmed/20128898
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1746-6148-6-8
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items